We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

126 hedge funds and large institutions have $1.62B invested in Recursion Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 52 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

420% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 10

382% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 11

132% more call options, than puts

Call options by funds: $2.03M | Put options by funds: $878K

100% more funds holding in top 10

Funds holding in top 10: 4 → 8 (+4)

50% more funds holding

Funds holding: 84 → 126 (+42)

28% more capital invested

Capital invested by funds: $1.26B → $1.62B (+$352M)

24.61% more ownership

Funds ownership: 34.53% → 59.14% (+25%)

Holders
126
Holders Change
+42
Holders Change %
+50%
% of All Funds
1.94%
Holding in Top 10
8
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+100%
% of All Funds
0.12%
New
53
Increased
52
Reduced
10
Closed
11
Calls
$2.03M
Puts
$878K
Net Calls
+$1.16M
Net Calls Change
+$101K

Top Buyers

1
BlackRock
BlackRock
New York
+$94M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$64M
3
State Street
State Street
Massachusetts
+$56.7M
4
AI
ArchPoint Investors
Florida
+$23.6M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$23.3M

Top Sellers

1
CL
CRV LLC
California
-$16.9M
2
Alkeon Capital Management
Alkeon Capital Management
New York
-$12.6M
3
YRHAM
Yong Rong (HK) Asset Management
Hong Kong
-$8.68M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.09M
5
AIM
ARK Investment Management
Florida
-$6.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
Baillie Gifford & Co
1
Baillie Gifford & Co
United Kingdom
$379M +$1.16M +61,781 +0.3%
BlackRock
2
BlackRock
New York
$116M +$94M +4,995,020 +283%
Vanguard Group
3
Vanguard Group
Pennsylvania
$105M +$64M +3,401,893 +125%
OMS
4
Obvious Management Services
California
$102M +$112M +5,977,631 New
DCI
5
Data Collective IV
California
$102M +$112M +5,941,120 New
State Street
6
State Street
Massachusetts
$79.8M +$56.7M +3,012,233 +183%
DOFI
7
DCVC Opportunity Fund II
California
$67.7M +$74.3M +3,951,141 New
LCM
8
Laurion Capital Management
New York
$67.2M – – –
AllianceBernstein
9
AllianceBernstein
Tennessee
$49.3M +$23.3M +1,236,478 +75%
AIM
10
ARK Investment Management
Florida
$38.2M -$6.81M -361,823 -14%
MMX
11
MV Management XI
California
$33.8M +$37.1M +1,971,908 New
TSV
12
Two Sigma Ventures
New York
$30.9M +$34M +1,806,800 New
CS
13
Credit Suisse
Switzerland
$26.7M +$2.05M +109,022 +8%
Fidelity Investments
14
Fidelity Investments
Massachusetts
$26.2M -$8.09M -429,737 -22%
HMC
15
Harvard Management Company
Massachusetts
$25.9M – – –
PIM
16
Platinum Investment Management
Australia
$24.7M +$14.7M +782,160 +118%
Norges Bank
17
Norges Bank
Norway
$23.9M +$16.9M +897,274 +179%
MCMU
18
MIC Capital Management (UK)
United Kingdom
$23.8M +$26.1M +1,388,889 New
Massachusetts Financial Services
19
Massachusetts Financial Services
Massachusetts
$22.3M +$7.6M +404,181 +45%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$22.2M +$13.8M +732,626 +130%
AI
21
ArchPoint Investors
Florida
$21.5M +$23.6M +1,255,430 New
CFM
22
Comprehensive Financial Management
California
$19M – – –
Northern Trust
23
Northern Trust
Illinois
$15.2M +$12M +635,290 +253%
T. Rowe Price Associates
24
T. Rowe Price Associates
Maryland
$14.7M +$5.21M +276,903 +48%
CC
25
Casdin Capital
New York
$9.39M – – –
1
2 3 4 5

RXRX Hedge Fund Activity: Q4 2021 in Review

126 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2021, worth a combined $1.62B — up 28% from $1.26B a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new RXRX positions and 11 closed out — a net gain of 42 holders — while 52 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, adding an estimated $94M. The largest seller was CRV LLC, exiting entirely with an estimated $16.9M sold.

  • 126 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2021, up from 84 in Q3 2021.
  • Funds reported $1.62B of Recursion Pharmaceuticals stock for Q4 2021, up 28% quarter-over-quarter.
  • 53 funds opened new Recursion Pharmaceuticals positions in Q4 2021 and 11 closed out, a net change of +42 holders.
  • The largest Recursion Pharmaceuticals buyer in Q4 2021 was BlackRock, an estimated $94M added.
  • The largest Recursion Pharmaceuticals seller in Q4 2021 was CRV LLC, an estimated $16.9M sold.

Based on aggregated 13F filings for Q4 2021.